Stay updated with breaking news from Morphosys Chief Research. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
EQS-News: MorphoSys AG / Key word(s): Conference MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in...
EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting 02.11.2023 / 14:05 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, Novemb...
MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis ...
EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer 12.09.2023 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, September 12, 2023 MorphoSys Receiv...
MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat ...